Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors-Reference-Cited by-同舟云学术

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Published:2019-10-15 Issue:12 Volume:145 Page:3021-3036
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Zhu Ning,Weng Shanshan,Wang Juan,Chen Jiaqi,Yu Linzhen,Fang Xuefeng,Yuan Ying^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-019-03044-5.pdf

Reference133 articles.

1. 33rd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Washington, DC, USA, 7–11 November 2018 (2018) J Immunother Cancer 6:114. https://doi.org/10.1186/s40425-018-0422-y

2. A Study of Atezolizumab in Combination with Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (IMmotion151) (2019). https://www.clinicaltrials.gov/ct2/show/NCT02420821

3. Amin A et al (2018) Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 6:109. https://doi.org/10.1186/s40425-018-0420-0

4. Arce Vargas F et al (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33:649 e644–663 e644. https://doi.org/10.1016/j.ccell.2018.02.010

5. Atkins MB et al (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19:405–415. https://doi.org/10.1016/s1470-2045(18)30081-0

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review;Cancers;2023-11-10

2. HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers;Gene;2023-11

3. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer;Biochemical Pharmacology;2023-09

4. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends;Signal Transduction and Targeted Therapy;2023-08-28

5. Efficacy of anti-programmed cell death protein 1 monoclonal antibody combined with bevacizumab and/or Pseudomonas aeruginosa injection in transplanted tumor of mouse forestomach carcinoma cell gastric cancer in mice and its mechanism in regulating tumor immune microenvironment;Clinical and Experimental Immunology;2023-07-01